Gupta AK, Mann A, Polla Ravi S, Wang T, Cooper EA. Efinaconazole 10% solution: a comprehensive review of its use in the treatment of onychomycosis.
Expert Opin Pharmacother 2024. [PMID:
39394930 DOI:
10.1080/14656566.2024.2416924]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2024] [Revised: 10/07/2024] [Accepted: 10/11/2024] [Indexed: 10/14/2024]
Abstract
INTRODUCTION
Onychomycosis is an infection of the nail bed and the nail plate. While oral antifungals are first-line for moderate to severe onychomycosis, topical efinaconazole 10% solution (JUBLIA®; Clenafin®) is effective and safe for mild to moderate severity onychomycosis. It is FDA-approved for patients aged 6 years and above.
AREAS COVERED
This literature review includes pharmacokinetics, microbiology, efficacy, safety, and post-marketing surveillance. It demonstrates consistent safety and efficacy across diverse patient demographics and comorbidities, including pediatric, diabetic and the elderly populations, without systemic side effects or drug interactions.
EXPERT OPINION
Efinaconazole 10% solution is an important addition to the armamentarium of therapies available to treat onychomycosis. Certain subgroups respond particularly well: females versus males, children versus adults, early onset onychomycosis (<1-year disease), those with mild onychomycosis (≤25% nail involvement), absence of tinea pedis, and thin nail plates at baseline (<1 mm thickness). Efinaconazole 10% solution is effective in diabetics and has demonstrated efficacy against dermatophytomas. Efinaconazole may be a consideration when terbinafine resistance is a concern, due to its different target of action.
Collapse